KRAS and Outcomes in Pancreatic Cancer

April 22, 2015
Mark Erlander, PhD

Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.

Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.

<<<

View more from the 2015 AACR Annual Meeting